Nocions which preferentially target activated sensory neurons that are responding to external insult

Nocion Therapeutics is pioneering a novel therapeutic approach through the development of "nocions," which are small molecules designed to selectively target and inhibit activated nociceptors—sensory neurons responsible for pain, itch, and cough. This innovative platform leverages the physiology of nociceptors, allowing nocions to enter these neurons via large-pore channels that open in response to external insults. Once inside, nocions effectively block sodium channels, providing targeted and sustained relief without affecting non-nociceptors. This mechanism aims to minimize off-target effects and reduce the risk of undesired side effects commonly associated with traditional local anesthetics.

The lead compound in Nocion's pipeline, taplucainium, exemplifies this approach as a charged sodium channel blocker formulated for inhalation. It is designed to access pulmonary nociceptors through various large-pore channels, inhibiting the sodium channels that trigger cough responses. Preliminary studies have shown promising results, including complete inhibition of cough in preclinical models and a favorable safety profile in clinical trials. Nocion's focus on conditions arising from neurogenic inflammation positions it to address significant unmet medical needs across various therapeutic areas, including chronic cough, pain, and dermatological conditions.

United States

Nocion Therapeutics is a biopharmaceutical company that is revolutionizing the treatment of conditions arising from neurogenic inflammation. The company is developing novel treatments for silencing neurons using a platform of unique molecular entities. Nocion Therapeutics is also focused on developing novel small molecule CSCBs, known as 'nocions', to address medical conditions related to neurogenic inflammation.

Nocion Therapeutics

Company Details